Screener
Inhibrx Biosciences, Inc. INBX Total Revenue
Discontinued — last reported Q4 '25
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:00 PM EDT
- Fiscal year
- FY2025
- Accession
- 0002007919-26-000006
| Line item | YEAR ENDEDDECEMBER 31, 2025 | YEAR ENDEDDECEMBER 31, 2024 |
|---|---|---|
| Revenue: | ||
| License fee revenue | $1,300 | $200 |
| Total revenue | 1,300 | 200 |
| Operating expenses: | ||
| Research and development | 113,028 | 203,743 |
| General and administrative | 23,297 | 127,905 |
| Total operating expenses | 136,325 | 331,648 |
| Loss from operations | (135,025) | (331,448) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Inhibrx Biosciences, Inc.'s total revenue?
- Inhibrx Biosciences, Inc. (INBX) reported total revenue of $0 in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s total revenue changed year-over-year?
- Inhibrx Biosciences, Inc.'s total revenue decreased by 100.0% year-over-year, from $100K to $0.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total revenue?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total revenue has grown at a -15.0% compound annual growth rate (CAGR), from $1.8M to $1.3M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Inhibrx Biosciences, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude